Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares

References

• Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29–42.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Harris RP, Forciea MA. For the clinical guidelines committee of the American College of Physicians. Management of acute and recurrent gout: A clinical practice guideline from the American College of Physicians. Ann Internal Med. 2017;166:58–68.
   PubMed Web of Science ®Google Scholar
• Znu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63:3136–3141.
   PubMed Web of Science ®Google Scholar
• Bardin T, Bouee S, Clerson P, et al. Prevalence of gout in the adult population of France. Arthritis Care Res. 2016;68:261–266.
   PubMed Web of Science ®Google Scholar
• Trifiro G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis. 2013;72:694–700.
   PubMed Web of Science ®Google Scholar
• Kuo CF, Grainge MJ, Mallen D, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74:661–667.
   PubMed Web of Science ®Google Scholar
• Colcrys [package insert]. Philadelphia, PA: AR Scientific, Inc. 2011
   Google Scholar
• Allopurinol oral tablets [package insert]. Memphis, TN: Northstar Rx LLC 2015
   Google Scholar
• Uloric [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc. 2013
   Google Scholar
• Probenecid oral tablets [package insert]. New Castle, DE: Marlex Pharmaceuticals, Inc. 2012
   Google Scholar
• Krystexxa [package insert]. Glendale, WI: Crealta Pharmaceuticals LLC 2016
   Google Scholar
• Zurampic [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP 2015
   Google Scholar
• Janssens HJEM, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. Lancet. 2008;371:1854–1860.
   PubMed Web of Science ®Google Scholar
• Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49:239–248.
   PubMed Web of Science ®Google Scholar
• Baker K, O’Rourke KS, Deodhar A. Joint aspiration and injection: a look at the basics. J Musculoskel Med. 2011;28:216–222.
   Google Scholar
• Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2012;4:252–256.
   Google Scholar
• Zhang S, Zhang Y, Liu P, et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systemic review and a meta-analysis. Clin Rheumatol. 2016;35:151–158.
   PubMed Web of Science ®Google Scholar
• Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Ther Clin Risk Manag. 2015;11:1061–1075.
   PubMed Web of Science ®Google Scholar
• Chan CW, Cheah XY. Treatment of acute gout in patients with coronary artery disease. Malays Fam Physician. 2013;8:44–46.
   PubMedGoogle Scholar
• American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227–2246.
   PubMed Web of Science ®Google Scholar
• Risser A, Donovan D, Heintzman J, et al. NSAID prescribing precautions. Am Fam Physician. 2009;80:1371–1378.
   PubMed Web of Science ®Google Scholar
• Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol. 2010;48:407–414.
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060–1068.
   PubMed Web of Science ®Google Scholar
• NIOSH [2016]. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. By Connor TH, MacKenzie BA, DeBord DG, Trout DB, O’Callaghan JP. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication Number 2016-161 (Supersedes 2014-138)
   Google Scholar
• Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects pf febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540–1548.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–2461.
   PubMed Web of Science ®Google Scholar
• Khanna PP, Fitzgerald J. Evolution of management of gout: a comparison of recent guidelines. Curr Opin Rheumatol. 2015;27:139–146.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Atxotegi J, Hernando I, et al. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate lowering therapy: a prospective study. Arthritis Rheum. 2006;55:786–790.
   PubMed Web of Science ®Google Scholar
• Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46:623–644.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Taylor WL, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64:2529–2536.
   PubMed Web of Science ®Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, et al. American College of Rheumatology guidelines for management of gout. Part 1: systemic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;2012(64):1431–1446.
   Web of Science ®Google Scholar
• Hung S, Chung WH, Liou LB, et al. HLA-B*5801 allel as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Nat Acad Sci. 2005;102:4134–4139.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [cited 2017 Apr 14]. Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Probenecid and colchicine tablets [package insert]. Allendale, NJ: Rising Pharmaceuticals, Inc., 2011
   Google Scholar
• Juraschek SP, Miller ER 3rd, Gelber AC. Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res. 2011;63:1295–1306.
   PubMed Web of Science ®Google Scholar
• Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711–720.
   PubMed Web of Science ®Google Scholar
• Baraf HS, Becker MA, Gutierrez-Urena SR, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013;15:R137.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16:R60.
   PubMed Web of Science ®Google Scholar
• Miner JN, Tan PK, Hyndman D, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18:214–223.
   PubMed Web of Science ®Google Scholar
• Tran TH, Pham JT, Shafeeq H, et al. Role of interleukin-1 inhibitors in the management of gout. Pharmacotherapy. 2013;33:744–753.
   PubMed Web of Science ®Google Scholar
• Keenan RT, Schlesinger N. New and pipeline drugs for gout. Curr Rheumatol Rep. 2016;18:32.
   PubMed Web of Science ®Google Scholar
• Dumusc A, So A. Interleukin-1 as a therapeutic target in gout. Curr Opin Rheumatol. 2015;27:156–163.
   PubMed Web of Science ®Google Scholar
• Schlesinger N. The safety of treatment options available for gout. Expert Opin Drug Saf. 2017;16:429–436.
   PubMed Web of Science ®Google Scholar
• Kineret [package insert]. Thousand Oaks, CA: Amgen, 2012
   Google Scholar
• Ghosh P, Cho M, Rawat G, et al. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res. 2013;65:1381–1384.
   PubMed Web of Science ®Google Scholar
• Singh D, Huston KK. IL-1 inhibition with anakinra in a patient with refractory gout. J Clin Rheumatol. 2009;15:366.
   PubMed Web of Science ®Google Scholar
• Gratton SB, Scalapino KJ, Fye KH. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum. 2009;61:1268–1270.
   PubMed Web of Science ®Google Scholar
• Tran AP, Edelman J. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis. 2011;14:e33–7.
   PubMed Web of Science ®Google Scholar
• So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9:R28.
   PubMed Web of Science ®Google Scholar
• Chen K, Fields T, Mancuso CA, et al. Anakinra’s efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum. 2010;40:210–214.
   PubMed Web of Science ®Google Scholar
• Khanna D, Khanna PP, Fitzgerald JD, et al. American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;2012(64):1447–1461.
   Web of Science ®Google Scholar
• Ilaris [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp., 2016
   Google Scholar
• Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71:1839–1848.
   PubMed Web of Science ®Google Scholar
• Wechalekar MD, Vinik O, Moi JH, et al. The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors. J Rheumatol Suppl. 2014;92:15–25.
   PubMedGoogle Scholar
• Arcalyst [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc. 2008
   Google Scholar
• Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-con- trolled, monosequence crossover, nonrandomised, single-blind pilot study. Ann Rheum Dis. 2009;68:1613–1617.
   PubMed Web of Science ®Google Scholar
• Terkeltaub R, Schumacher HR, Carter JD, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther. 2013;15:R25.
   PubMed Web of Science ®Google Scholar
• Sivera F, Wechalekar MD, Andrés M, et al. Interleukin-1 inhibitors for acute gout. Cochrane Database of Systematic Reviews. 2014;9:CD009993.
   Google Scholar
• Delenex expands pipeline with anti-IL-17A and anti-IL-1β PENTRA®Body programs. [cited 2017 Apr 11]. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=549422
   Google Scholar
• Bree APK, Benson M, Dower K, et al. Pharmacological inhibition of interleukin-1 receptor-associated kinase-4 reduces inflammation in a murine model of gout and is consistent with IL-1 signaling blockade. Arthritis Rheum. 2011;63(Suppl 10):1621.
   Google Scholar
• Guarda G, Dostert C, Staehli F, et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature. 2009;460:269–273.
   PubMed Web of Science ®Google Scholar
• Drug discovery pipeline: IL-1 beta candidate immunereszumab. Immune Response BioPharma, Inc. [cited 2017 Apr 11]. Available from: http://www.immuneresponsebiopharma.com/Pages/Immunereszumab.aspx
   Google Scholar
• Gagné V, Marois L, Levesque JM, et al. Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications. Arthritis Res Therapy. 2013;15:R73.
   PubMed Web of Science ®Google Scholar
• Battle erupts over how to treat gout, no longer the ‘disease of kings’. [cited 2017 Apr 7]. Available from: https://www.statnews.com/2017/01/25/gout-treatment-doctors-battle/
   Google Scholar